Why Castle Biosciences' Rally Might Just Be Getting Started
1. Castle Biosciences (CSTL) gained over 20% after a strong Q3 performance. 2. The stock is in Phase 8, indicating bullish momentum per Adhishthana Principles. 3. CSTL could reach $35, starting Phase 9 before January 2026. 4. Investors are advised to maintain bullish positions and explore accumulation opportunities. 5. Positive momentum is expected in the upcoming Buddhi period starting December 2025.